Investors

Copyright Nasdaq. Minimum 15 minutes delayed.

Investor Overview

OvaScience is focused on developing novel treatments for women and couples struggling with infertility. These treatments are based on a proprietary technology platform that leverages the breakthrough discovery of egg precursor cells – immature egg cells found within the outer ovarian cortex. In March 2018, the Company announced preliminary blinded data for its Phase 1 trial of OvaPrime for women with primary ovarian insufficiency and poor ovarian response. This trial was not expected to result in strong signals on secondary endpoints. The Company has since completed additional preclinical studies and based on results from these studies, has scaled back investment in its research and development efforts to focus on evaluating strategic alternatives.  In August 2018, the Company announced that it entered into a definitive agreement with Millendo Therapeutics to create a leading rare endocrine disease company. The transaction has been approved by the board of directors of both companies.  It is expected to close in the fourth quarter of 2018, subject to the approval of OvaScience shareholders at a special shareholder meeting, as well as other customary conditions. 

More »

Recent News

Date Title and Summary  
Toggle Summary OvaScience Reports Second Quarter 2018 Financial Results and Provides Strategic Alternatives Update
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 9, 2018-- OvaScience SM (Nasdaq:OVAS), a company focused on developing novel treatments for women and couples struggling with infertility, today reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of
View HTML
Toggle Summary OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
– Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi Syndrome – – Companies to Host Conference Call to Discuss Transaction at 8:30 a.m. ET – WALTHAM, Mass. & ANN ARBOR, Mich. --(BUSINESS WIRE)--Aug.
View HTML
Toggle Summary OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2018-- OvaScience SM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
– Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial – – Appointed James Lillie, Ph.D. as Chief Scientific Officer to Lead Advancement of OvaTure
View HTML

More »

Upcoming Events

There are currently no events to display.
There are currently no events to display.